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for the intervention and comparator arms were sourced from relevant clinical tri-
als; survival was assumed to follow an exponential distribution. Representative 
acquisition, administration, and monitoring costs were sourced from the litera-
ture and health technology assessment appraisals. The maximum CEP for each 
analogue was evaluated at two different willingness-to-pay (WTP) thresholds: 
£20,000/QALY and £50,000/QALY. All costs and outcomes were discounted at 
3.5%. RESULTS: The results from the early economic model suggested that neither 
pertuzumab nor trametinib would ever be a cost-effective therapy even at a WTP 
threshold of £50,000. However, at both WTP thresholds of £20,000 and £50,000/
QALY, idelalisib was projected to have a cost-effective price, which was similar 
to the current list price in the UK. CONCLUSIONS: These results demonstrate 
that neither pertuzumab nor trametinib have CEPs, while the CEP for idelalisib is 
similar to the UK launch price, demonstrating that add-on branded therapies co-
administered without anchors dosed to progression (here, rituximab) will permit 
higher prices while remaining cost-effective. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early 
in the development process.
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OBJECTIVES: The purpose of this study was to evaluate the maximum cost-effective 
price (CEP) supported for innovative drugs co-administered with existing branded 
therapies. METHODS: An early economic model was constructed in Microsoft 
Excel using a three-state partitioned-survival approach. The intervention arm was 
assumed to be a hypothetical regimen consisting of an add-on drug and an anchor 
branded therapy, while the comparator consisted of the anchor therapy; both arms 
were dosed to progression. Three pricing scenarios were evaluated for the anchor: 
£1,000/month (low cost), £3,000/month (moderate cost), and £5,000/month (high 
cost). Other costs were sourced from a literature review; adverse event costs were 
not included. Progression-free survival (PFS) and overall survival (OS) were modelled 
assuming an exponential distribution; different median PFS and OS gains were 
evaluated to determine the maximum cost-effective price permitted for the add-on 
therapy. The maximum supported price was evaluated at two different willingness-
to-pay (WTP) thresholds: £20,000/QALY and £50,000/QALY. All costs and outcomes 
were discounted at 3.5%. RESULTS: For small gains in OS and PFS (< 3 months), the 
model projects that no CEP for the add-on would be supported at a WTP threshold 
of £20,000/QALY. When administered with a low-cost anchor, the add-on would 
be cost-effective at a WTP of £50,000/QALY with a price up to £583/month; when 
administered with a high-cost therapy, no CEP was supported. In order to sup-
port any CEP for the add-on, substantial gains in OS are required: for a PFS gain 
of 3 months, a gain of 6.9 months for OS would be required at a WTP of £50,000/
QALY. CONCLUSIONS: These results demonstrate that new drugs co-administered 
with anchor branded therapies require substantial OS gains to support cost-effective 
pricing, as these drugs are dosed to progression. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early in 
the development process.
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OBJECTIVES: To evaluate a new empirical algorithm for selecting disease-
related medical billing codes associated with chronic lymphocytic leukemia 
(CLL). METHODS: Patients in the SEER-Medicare database with a CLL diagnosis 
(2002 to 2010) were age/gender matched to a non-cancer sample. A proprietary cod-
ing algorithm based on code frequency (sensitivity, specificity precision or accuracy) 
and cost was used to identify procedure (i.e., CPT and HCPCS) and diagnosis (ICD-
9-CM) codes that differed between the CLL and non-cancer groups. Summarized 
costs for claims with the empirically identified codes were compared to a traditional 
approach of identifying disease-related claims based on presence of a CLL diagnosis 
in the first diagnosis field. The code set was applied to a sample from a prior CLL 
study conducted with commercial claims to assess generalizability. RESULTS: The 
analysis evaluated 10,531 unique billing codes with total costs of > $1 billion (US; CLL 
58.3%; non-cancer 41.7%) for 7,050 age and gender matched SEER-Medicare subjects 
per group. The empirical algorithm found 333 codes that identified 25.0% of the CLL 
group costs as cancer-related. The traditional approach used claims that contained 
2,001 codes and identified a much lower 14.6%. Approximately 1% of costs were 
potentially misidentified in the non-cancer cohort, providing further confirmation 
of the codes selected by the empirical method. Qualitative review of codes revealed 
stronger content validity with the empirical approach compared to the traditional 
approach. Application of codes identified in the SEER-Medicare data to the com-
mercial database provided validation by identifying almost twice as many costs 
as the traditional approach with a 1% error rate. CONCLUSIONS: The traditional 
approach underreports costs and captures costs from procedure codes that do not 
appear to be cancer-related. Use of an empirical approach to identify disease-related 
diagnosis and procedure codes will increase content validity.
PCN101
hosPitAl utilizAtioN iN PAtiENts with mANtlE CEll lymPhomA
Belk K.1, Craver C.W.2
1MedAssets, Mooresville, NC, USA, 2MedAssets, Inc., Huntersville, NC, USA
OBJECTIVES: To examine hospital utilization in patients diagnosed with mantle 
cell lymphoma (MCL). METHODS: A retrospective cross-sectional study was con-
cTACE strategy was estimated to be 414 days whereas that of DEB TACE strategy was 
estimated to be 651 days. The total costs for cTACE strategy and DEB TACE strategy 
were EGP 420,529 and EGP 1,351,105 respectively. Thus the incremental cost effec-
tiveness ratio (ICER) for cTACE versus DEB TACE is EGP 3,926 per one day survival 
gained. The Deterministic sensitivity analysis demonstrated that survival associated 
by DEB TACE strategy and DEB-TACE operation costs have the greatest effect on the 
results. CONCLUSIONS: Results from this study suggest that employing a cTACE 
strategy is cost-effective intervention compared to DEB TACE in patients with hepa-
tocellular carcinoma based on the willingness to pay threshold stated by world health 
organization (3xGDP/capita) for low and middle income countries.
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OBJECTIVES: Pricing and reimbursement is typically approached product by prod-
uct, not in comparison across therapeutic areas in Peru. Within oncology, there are 
relatively few treatment options for advance stage cancer patients that have docu-
mented significant increases in overall survival (OS). Ipilumumab has been recently 
approved in Peru for the treatment of unresectable or metastatic melanoma. Given 
the rising costs of cancer care payers and physicians need to better understand 
the value of innovative oncology drugs for reimbursement decision making. This 
study assesses the cost per additional month of mean overall survival of ipilimumab 
and how this metric compares to other oncology agents approved in Peru in the 
metastatic setting. METHODS: We selected agents that received regulatory authori-
zation in the last 10 years in Peru and had phase 3 studies with OS as a primary or 
secondary objective. Mean OS was obtained from published literature. Drug prices 
were obtained from “observatorio de precios de DIGEMID” a public database. The 
economic value of each asset is presented in terms of cost per additional month of 
mean OS from a private healthcare payer perspective. The analysis uses the cost 
to treat to mean progression of each agent divided by the months of mean overall 
survival improvement using its current list price. All prices are in 2014 “nuevos 
soles” RESULTS: Seventeen drugs met inclusion criteria. Of these, 26 different indi-
cations were evaluated. The average cost per mean overall survival month gained 
was estimated at S/.57,178, range S/.3,108 – S/.264,764. Ipilimumab as first and sec-
ond line treatment for metastatic melanoma had an estimated cost per additional 
mean overall survival at S/.36,901 and S/.41,740 respectively. CONCLUSIONS: In 
this cost efficacy analysis, Ipilimumab´s cost per additional month of overall sur-
vival was estimated below the market average. At current private market prices 
Ipilimumab may offer good value for money.
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OBJECTIVES: Recent findings show that vaccinating older men who have sex with 
men (MSM) with history of high-grade anal intraepithelial neoplasia (HGAIN)–a 
precursor to anal cancer–with quadrivalent human papillomavirus (qHPV) vac-
cine was associated with 50% decrease in the hazards for recurrent or persistent 
HGAIN. We evaluated the long-term clinical and economic outcomes of adding 
qHPV vaccine to the HGAIN treatment regimen HGAIN in HIV-positive MSM aged ≥ 
27 years. METHODS: Using Markov model of anal histology in HIV-positive MSM we 
compared two strategies–no qHPV vaccination after treatment for HGAIN versus 
qHPV vaccination after treatment for HGAIN. The probability of anal intraepithelial 
neoplasia (AIN) progression was conditional on patients’ CD4 count. Model param-
eters, including baseline prevalence, disease transitions, costs, and utilities were 
either obtained from literature or calibrated using a natural history model of anal 
carcinogenesis. Model output included lifetime costs, quality-adjusted life years 
(QALYs), and lifetime risk of developing invasive cancer. Results from the healthcare 
perspective were presented in the forms of incremental cost-effectiveness ratios 
(ICERs) and decrease in lifetime risk of anal cancer. Deterministic and probabilistic 
sensitivity analyses were conducted on model parameters. RESULTS: Vaccination 
after treatment for HGAIN decreased the lifetime risk of anal cancer by 63% com-
pared to the no vaccination strategy. Vaccination resulted in the decrease in lifetime 
costs with increase in effectiveness by 0.16 QALYs. The predicted incidence of anal 
cancer after vaccination was almost one-third to that of the no vaccination strategy. 
The results were sensitive to the model parameters–progression from HGAIN to 
cancer, mortality attributed to anal cancer, cost of HGAIN treatment, and discount 
rate. CONCLUSIONS: Vaccinating the high-risk population of HIV-positive MSM aged 
≥ 27 after treatment for HGAIN is a cost-saving strategy. Expansion of current vac-
cination guidelines to include this population should be a priority.
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OBJECTIVES: The purpose of this study was to develop an early economic model to 
compare the maximum supported cost-effective prices (CEP) of recently launched 
co-administered branded products to their list prices in the UK. METHODS: An 
early economic model was constructed in Microsoft Excel using a three-state 
partitioned-survival approach. A pragmatic literature search was performed iden-
tified three co-administered branded therapies as case studies: pertuzumab + 
trastuzumab(+docetaxel) in HER2+ breast cancer, trametinib + dabrafenib in mela-
noma, and idelalisib + rituximab in chronic lymphocytic leukaemia; all therapies 
except rituximab were dosed to progression. Progression-free and overall survival 
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OBJECTIVES: To estimate the value of survival gains in myelodysplastic syndromes 
(MDS) attributable to the introduction of azacitidine (2004), lenalidomide (2005), 
and decitabine (2006). METHODS: Using multivariate Cox proportional hazards 
models we estimated the increase in survival associated with the introduction 
of new therapies for MDS patients diagnosed from 2001–2011 in the Surveillance, 
Epidemiology, and End Results program registries. The key variable in the haz-
ard model was the post-2006 indicator, which captured the increase in survival 
associated with the introduction of the 3 therapies relative to years 2001–2003. 
Importantly, we included flexible specifications of time trends to capture secular 
changes in survival over the study period. We estimated the cost and utiliza-
tion of the 3 therapies from 2006–2012 using the Optum Touchstone commercial 
claims database. RESULTS: For 38,085 MDS patients diagnosed in 2001 or later 
we estimated that the introduction of these 3 therapies was associated with a 
hazard ratio of 0.901 (p< 0.10). Approximately 25% of MDS patients used at least 
1 of the 3 treatments over this period, implying an increase in median survival 
from 33 to 57.5 months, conditional on treatment observed in the community. 
Using an existing economic model to value survival gains, we estimated that 
the annual value of survival gains associated with the new therapies—i.e., the 
amount patients would be willing to pay for the improved survival profile—
equaled $208,000 per year. Based on this, we estimate the net present value 
of the therapies to all future patients at $101.5 billion. Net of treatment costs, 
85% of the total value accrues to patients. CONCLUSIONS: This study meas-
ured the value of survival gains attributable to 3 novel therapies for MDS and 
found significant benefits. For current and future MDS patients, these thera-
pies will generate $101.5B in value from survival gains, with 85% accruing to 
patients.
CANCEr – Patient-reported outcomes & Patient Preference studies
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OBJECTIVES: Comprehensive Medicaid population based studies of adherence 
and persistence to tamoxifen and aromatase inhibitors (AIs) including anastro-
zole, exemestane, and letrozole among women with breast cancer are currently 
lacking. The purpose of this study was to estimate the adherence and persistence 
to tamoxifen and AIs among women with breast cancer enrolled across 38 state 
Medicaid programs. Factors predicting adherence and persistence to tamoxifen 
and AIs were also determined. METHODS: Study population included women aged 
18-64 years who were continuously enrolled for a period of three years (2006-2008) 
in Medicaid managed care program across 38 states. Incident users of tamoxifen 
and AIs in 2007 were identified. To assess adherence (proportions of days covered) 
and persistence (gap between prescription refills) to tamoxifen and/or AIs among 
the final sample of women recipients with breast cancer, prescription drug claims 
from index date to 12-month post index date were studied. Logistic regression was 
used to identify predictors of adherence and persistence, respectively. RESULTS: 
Roughly 56% of women with breast cancer were adherent with tamoxifen 
and/or AIs therapy. Higher age, white race (versus black), geographic location in 
Northeast region (versus South, Midwest, and West region), stage II or III/IV (ver-
sus stage 0), and higher number of outpatient visits were associated with higher 
adherence in the regression model. More than three-fourths (~77%) of women 
with breast cancer were persistent with tamoxifen and/or AIs therapy. Regression 
analysis revealed that women with breast cancer residing in Northeast region 
(versus South and West region) and with stage I or III/IV cancer (versus stage 0) 
were more likely to be persistent with therapy. CONCLUSIONS: Adherence and 
persistent to tamoxifen and AIs was less than optimal among women with breast 
cancer enrolled in Medicaid programs. Policy makers should consider implement-
ing interventions aimed at increasing treatment adherence and persistence among 
this population.
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OBJECTIVES: Lenalidomide is a disease-modifying oral medication approved 
for the treatment of multiple myeloma as well as other myelodysplastic syn-
dromes. A CarePak® is a drug regimen packaging tool that simplifies complex 
drug regimens for patients. This tool is frequently used for patients receiving 
drug regimens containing lenalidomide. The impact of this tool on duration of 
therapy has previously not been studied. METHODS: This study was a retro-
spective review of pharmacy claims data. Eligible patients included those who 
filled a lenalidomide prescription more than once, did not have a gap between 
fills longer than 60 days. Patients receiving a CarePak® must have received one 
with all of their dispenses and for at least 6 consecutive months. Duration of 
therapy was calculated as the time between a patient’s first and last fill, includ-
ing the most recent day’s supply. RESULTS: A random sample of patients filling 
between 2009 and 2014 was used for this analysis. To assess differences in dura-
tion of therapy, 225 patients receiving CarePaks® and 225 patients not receiving 
CarePaks® were identified. Duration of therapy for patients utilizing CarePaks® 
and for patients not utilizing CarePaks® was10.5 months and 8.4 months respec-
tively, representing a difference of 2.1 months (p = 0.001). CONCLUSIONS: The 
use of CarePaks® significantly improved duration of therapy in patients receiving 
lenalidomide compared to patients not using CarePaks®. The result of this analysis 
suggests a need for further investigation into the impact of CarePaks® on patient 
outcomes.
ducted on the MedAssets health system data for inpatient and outpatient visits 
diagnosed with MCL for the January 2009 to December 2014 timeframe. Age and 
gender, clinical comorbidities and measures of utilization including number of 
visits and length of stay (LOS) were described. Multivariable regression was used to 
identify significant drivers of hospital-based utilization. RESULTS: The MCL popula-
tion consisted primarily of males (70.8%) and had a mean age of 66 years. Of 35,762 
visits 84.6% occurred in the outpatient setting. Infection (OR= 7.4, p< .0001), fluid and 
electrolyte disorders (OR= 6.3, p< .0001), plegia (OR= 5.9, p< .01), myelosuppression 
(OR= 5.2, p< .0001) and nutritional deficiencies (OR= 3.3, p< .0001) were associated 
with inpatient admissions. The most common complications of treatment included 
myelosuppression (21.7%), gastrointestinal issues (GI, 7.3%), infection (4.9%) and 
renal deficiency (4.8%). Pharmacy (49.2%), room and board (12.8%), laboratory testing 
(10.2%), diagnostic services (7.8%), and surgery (5.8%) costs were the most common 
in this population. When patients were admitted the average LOS was 8.3 days with 
an average cost of $18,291 and 5.0% in-hospital mortality rate. During inpatient hos-
pitalizations 55.0% received chemotherapy, 26.1% had a blood transfusion, 5.2% had 
a bone marrow biopsy, 4.4% had a stem cell transplant, 2.3% had hemodialysis and 
1.5% had radiotherapy. Nutritional deficiencies (IRR= 1.55, p< .0001), plegia (IRR= 1.51, 
p< .0001), infection (IRR= 1.46, p< .0001), myelosuppression (IRR= 1.34, p< .0001) and GI 
(IRR= 1.3, p< .0001) were associated with longer LOS. Readmissions occurred within 
30 days for 28.6% of inpatient admissions with 41.4% of readmissions having main-
tenance chemotherapy or radiotherapy as the primary diagnosis. CONCLUSIONS: 
MCL patients primarily use outpatient services. Inpatient services are required to 
treat complications of treatment such as myelosuppression and infections as well 
as to provide follow-up treatments and care.
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OBJECTIVES: The objective of this analysis was to describe hospital-based resource 
utilization among a population of patients with polycemia vera (PCV). METHODS: 
A retrospective cohort analysis was conducted on a cross-section of patients using 
hospital-based inpatient (N= 7974) and outpatient (N= 47078) services between 2013 
and 2014 with a diagnosis of PCV. Multivariate logistic regression was used to evalu-
ate risk factors for readmission controlling for patient and hospital characteristics 
as well as patient comorbidities. RESULTS: The mean age for PCV patients was 64.4 
years with 58.5% male. Utilization was highest in the OP setting (85.5%) with 68.3% of 
OP visits having a primary diagnosis of PCV. The primary diagnosis for IP admissions 
varied with the most common including infectious and parasitic diseases (6.6%), 
cerebrovascular disease (6.2%), chronic obstructive pulmonary disease (5.5%), heart 
failure (5.2%) and ischemic heart disease (5.2%). PCV patients were primarily treated 
in large (68.4%) and teaching (60.3%) hospitals. The mean Charlson comorbidity 
score was 1.6 with chronic pulmonary disease (18.4%), diabetes (16.7%), congestive 
heart failure (10.3%), cardiovascular disease (10.0%) and renal disease (10.0%) as the 
most common comorbidities. Readmissions occurred within 30 days for 9.0% of IP 
visits for a variety of diagnoses including rehabilitation services (10.9%), chest pain/
shortness of breath (6.8%), infectious and parasitic diseases (4.9%), cerebrovascu-
lar disease (4.1%) and respiratory failure (3.9%). Chronic pulmonary disease (OR = 
1.25, p< .05), hemiplegia or paraplegia (OR = 1.73, p< .05), renal disease (OR = 1.51, 
p< .001) and abdominal drainage procedures (OR = 2.60, p< .01) were associated with 
increased occurrence of readmission. CONCLUSIONS: PCV is primarily managed 
in the community or OP setting. As PCV-related complications develop patients are 
admitted for IP services. These patients are frequently readmitted within 30 days.
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OBJECTIVES: To estimate the economic impact in the treatment of Colombian 
patients with Non-Hodgkin lymphoma developing a time and motion study for the 
IV administration versus subcutaneous (SC) presentation of rituximab. METHODS: 
Time and motion study, observational, multicentric (two private hospitals, one pub-
lic hospital), non-interventional describing costs and times from the admission of 
the patient until their discharge, recording healthcare professionals (HPC), drugs, 
consumables and procedures room. Population evaluated were patients in first 
chemotherapy with rituximab IV with diffuse large B-cell lymphoma and follicu-
lar lymphoma, in regular cycles and in maintenance phase. Finally, we calculated 
the time and cost differences of the treatment of patients with SC (drug still non 
approved in Colombia, therefore these data was obtained from Rule et al., 2014) 
instead IV rituximab from the perspective of the provider. RESULTS: Patients were 
treated with rituximab IV at doses between 520 mg and 700 mg. If they had been 
treated with SC, it estimated to cause net savings of $360 USD per patient, which 
were represented in costs of healthcare professionals (HPC), drugs, consumables 
and procedures room and around 207 minutes of total time expenditure. The cost 
of rituximab SC is the most important savings factor to the provider because it is 
administrated at constant doses non-weight depended. CONCLUSIONS: Rituximab 
SC was a cost-saving strategy for the providers compared with Rituximab IV. As 
results of the savings in cost of treatment, consumables, procedures room and total 
time expenditure, the actual resources of the health provider could be optimized.
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